Table 1. Baseline characteristics of the study participants.
| Baseline characteristics | median (range) or n/total (%) |
|---|---|
| Age (years) | 33 (20–45) |
| Mode of transmission | |
| Heterosexual | 86 / 94 (92%) |
| Blood transfusion | 1 / 94 (1%) |
| MTCT | 2 / 94 (2%) |
| Unknown | 5 / 94 (5%) |
| Geographical origin | |
| Sub-Saharan African | 80 / 94 (85%) |
| Caucasian | 8 / 94 (9%) |
| Maghrebin | 4 / 94 (4%) |
| Asian | 2 / 94 (2%) |
| Medical insurance coverage | |
| General social security coverage | 58 / 94 (62%) |
| Universal Medical Coverage (CMU) | 21 / 94 (22%) |
| State Medical Aid (AME) | 12 / 94 (13%) |
| None | 3 / 94 (3%) |
| HIV Co-infections | |
| HIV / HBV | 5 / 94 (5%) |
| HIV / HCV | 0 / 94 (0%) |
| First HIV-RNA during pregnancy (copies/mL) | |
| Women with HIV-RNA < 50 copies/mL (n) | 38 / 94 (40%) |
| Women with HIV-RNA > 50 copies/mL (n) | 56 / 94 (61%) |
| Detectable HIV-RNA (copies/mL) | 9823 (63–638388) |
| First CD4 T-cell count during pregnancy (/mm3) | 448 (4–986) |
| cART History | |
| Naïve | 16 / 94 (17%) |
| Treatment-experienced | 78 / 94 (83%) |
| Obstetrical history | |
| Number of previous pregnancy (n) | 3 (1–8) |
| Previous twin or multiple pregnancy | 2 / 94 (2%) |
MTCT, Mother-To-Child Transmission; cART, combined Antiretroviral Therapy.